Search
PAS-004
go.drugbank.com/drugs/DB18611InvestigationalPAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
MC-1
go.drugbank.com/drugs/DB05315ExperimentalMedicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.
Eperisone
go.drugbank.com/drugs/DB08992InvestigationalIt is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.
Methionine
go.drugbank.com/drugs/DB00134ApprovedInvestigationalNutraceuticalA sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Methoxamine
go.drugbank.com/drugs/DB00723ApprovedInvestigationalWithdrawnAn alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system.
Ethionamide
go.drugbank.com/drugs/DB00609ApprovedInvestigationalWithdrawnA second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
Poloxalene
go.drugbank.com/drugs/DB11451InvestigationalVet approvedIt belongs to the family of Epoxides. These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms).
CZEN 002
go.drugbank.com/drugs/DB05479Experimental(6-9) that is important for binding to the known melanocortin receptors. … It appears that CZEN-002 works on a receptor in yeast that has yet to be identified.
Otelixizumab
go.drugbank.com/drugs/DB05496InvestigationalOtelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance
MRK-003
go.drugbank.com/drugs/DB17015ExperimentalMRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]